ATRS - Antares Pharma posts Q1 earnings beat maintains FY revenue forecast

Antares Pharma (ATRS) posted first-quarter results that beat Wall Street estimates, as the company benefited from an increase in prescriptions and patient visits due to the slowdown of the COVID-19 pandemic.The company also reaffirmed FY 2021 revenue guidance in the range of $175M-200M, which represents a 17% to 34% year-over-year growth rate and assumes no significant disruptions to supply or operations due to the ongoing  pandemic."With XYOSTED total prescription growth of 50% year-over-year, we expect to continue to build positive momentum throughout the year as patient visits to physician offices increase and our sales representatives garner more in-office physician details, and as vaccines are administered and the pandemic slows," CEO Robert Apple said.XYOSTED revenue in the first quarter 2021 increased 60% year-over-year to $14.4M, according to IQVIA.Teva’s generic EpiPen prescriptions in the first quarter 2021 increased 48% year-over-year, contributing to a 40% increase in EpiPen product and royalty revenue.Total revenue in the

For further details see:

Antares Pharma posts Q1 earnings beat, maintains FY revenue forecast